| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human Cystatin D-protein was developed from hek293. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 Mu m filtered PBS solution, pH7.2, 5% Trehalose. |
| Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: |
Can be stored in working aliquots at 2°C-8°C C for one month, or at-20°C to-70°C for 1 year. Avoid repeated freeze/thaw cycles. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunoreactivity: |
The activity was tested by the ability to inhibit papain cleavage of a fluorogenic substrate. The ED50 was measured to NA |
| Gene Symbol: |
CST5 |
| Gene ID: |
1473 |
| Uniprot ID: |
CYTD_HUMAN |
| Immunogen Region: |
GLY21-VAL142 |
| Immunogen: |
Optimized DNA sequence encoding Human Cystatin D-CST5 (GLY21-VAL142 ) mature chain including a C-terminal His tag was expressed in HEK293 cells. NA |
| Tissue Specificity | Expressed in submandibular and sublingual saliva but not in parotid saliva (at protein level). Expressed in parotid gland but not in seminal vesicle, prostate, epididymis, testis, ovary, placenta, thyroid, gastric corpus, small intestine, liver, or gall bladder tissue. |
| Function | Cysteine proteinase inhibitor that possibly plays a protective role against proteinases present in the oral cavity. The order of preference for inhibition is cathepsin S > cathepsin H > cathepsin L > cathepsin B. |
| Protein Name | Cystatin-DCystatin-5 |
| Cellular Localisation | Secreted |
| Alternative Protein Names | Cystatin-D proteinCystatin-5 proteinCST5 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
